Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how chronic kidney disease elevated the risk of vascular calcification and what the risks of vascular calcification are.
Dr. Cary Boyd-Shiwarski explains how nonsteroidal mineralcorticoid receptor antagonists and novel potassium-binding agents alter the management of hyperkalemia and approaching potassium handling in chronic kidney disease.
Drug dose and monitoring should be individualized based on patients’ unique bone marrow health profile with their age, comorbidities, and prior marrow toxic drug use accounted for.
In addition to the vital clinical role that pharmacists play, Mei Ka Fong, PharmD, BCOP, said pharmacists are essential to ensuring that patients understand their disease and their treatments.
Boyd gave a general overview of how potassium handling works in chronic kidney disease, specifically with hyperkalemia.
Farzana Perwad, MD, chief of the Division of Nephrology at UCSF Benioff Children's Hospitals, discusses the common health impacts of phosphate metabolism disorders.
Farzana Perwad, MD, chief of the Division of Nephrology at UCSF Benioff Children's Hospitals, discusses the relationship between chronic kidney disease and disorders of phosphate metabolism.
Despoina Manousaki, MD, PhD, pediatric endocrinologist and assistant professor at CHU Sainte-Justine Research Centre, discusses the impact of uremia on vitamin D metabolism.
Despoina Manousaki, MD, PhD, pediatric endocrinologist and assistant professor at CHU Sainte-Justine Research Centre, discusses the relationship between uremia and chronic kidney disease.
Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses next steps in research investigating the benefits of aspirin in patients with chronic kidney disease.
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, why submaximal dosing is important in minimizing proteinuria and chronic kidney disease.
Tidutamab was found to have favorable safety and tolerability treating neuroendocrine tumors of pancreatic, gastrointestinal, lung, and undetermined origin.
Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses the implications of study results assessing long-term aspirin use and the progression of kidney disease.
Mei Ka Fong, PharmD, BCOP, said that although many potential adverse events are well understood in patients receiving traditional treatments, there are no studies investigating the sequencing of these agents.
Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, discusses what the study results demonstrated regarding treating carcinoid crisis without perioperative octreotide for patients with neuroendocrine tumors.
Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses the study findings regarding how the long-term use of aspirin impacts mortality and renal deterioration in patients with chronic kidney disease.
Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses what patient populations were included in the study assessing the long-term use of aspirin in patients with chronic kidney disease.
Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, discusses what the study results demonstrated regarding treating carcinoid crisis without perioperative octreotide for patients with neuroendocrine tumors.
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, why providers might under dose ACE and ARB treatments for proteinuria.
Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses the selection of the patient populations included in the study of carcinoid crisis with no perioperative octreotide.
Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses the established understanding of how the use of aspirin impacts the treatment of chronic kidney disease.
Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, discusses her presentation at the American Society of Nephrology’s Kidney Week 2021 on the association between long-term aspirin use and the progression of kidney disease.
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, discusses the similarities and differences of ACEs and ARBs in practice.
Galindo hopes that less patients will be diagnosed with advanced chronic kidney disease if we use the right glucose-lowering agents in the earliest stages.
Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses next steps in potential future research avenues following the results of her analysis into the risk of hematuria and proteinuria associated with rosuvastatin use.
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, discusses how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses the results of her research regarding the risks of hematuria and proteinuria with rosuvastatin use.
Galindo explained how the use of glucose-lowering agents in patients with diabetes and low eGFR improved patient care.
The FDA is currently reviewing a New Drug Application for vadadustat in this patient population, and a Prescription Drug User Fee Act date has been set for March 29, 2022.
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how targeted therapies are impacting the treatment of NETs.
